MIRAPEXIN 0.18 mg TABLETS
How to use MIRAPEXIN 0.18 mg TABLETS
Translated with AI
This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.
Show originalContents of the leaflet
Introduction
Leaflet: information for the user
MIRAPEXIN 0.088 mg tablets
MIRAPEXIN 0.18 mg tablets
MIRAPEXIN 0.35 mg tablets
MIRAPEXIN 0.7 mg tablets
pramipexole
Read the entire leaflet carefully before starting to take this medication, as it contains important information for you.
- Keep this leaflet, as you may need to read it again.
- If you have any questions, consult your doctor or pharmacist.
- This medication has been prescribed to you only, and you should not give it to others, even if they have the same symptoms as you, as it may harm them.
- If you experience side effects, consult your doctor or pharmacist, even if they are not listed in this leaflet. See section 4.
Contents of the leaflet
- What is MIRAPEXIN and what is it used for
- What you need to know before taking MIRAPEXIN
- How to take MIRAPEXIN
- Possible side effects
- Storage of MIRAPEXIN
- Package contents and additional information
1. What is MIRAPEXIN and what is it used for
MIRAPEXIN contains the active substance pramipexole and belongs to a group of medicines called dopaminergic agonists, which stimulate dopamine receptors in the brain. Stimulation of dopaminergic receptors triggers nerve impulses in the brain that help control body movements.
MIRAPEXIN is used to:
- treat symptoms of idiopathic Parkinson's disease in adults. It can be used alone or in combination with levodopa (another medication for Parkinson's disease).
- treat symptoms of moderate to severe idiopathic restless legs syndrome in adults.
2. What you need to know before taking MIRAPEXIN
Do not take MIRAPEXIN
- if you are allergic to pramipexole or any of the other components of this medication (listed in section 6).
Warnings and precautions
Consult your doctor before starting to take MIRAPEXIN. Inform your doctor if you have or have had any disease or symptom, especially any of the following:
- Kidney disease.
- Hallucinations (seeing, hearing, or feeling things that are not present). Most hallucinations are visual.
- Dyskinesia (e.g., abnormal involuntary movements of the limbs). If you have advanced Parkinson's disease and are also taking levodopa, you may experience dyskinesia during the gradual increase in the dose of MIRAPEXIN.
- Dystonia (inability to keep the trunk and neck straight and upright [axial dystonia]). In particular, you may experience forward flexion of the head and neck (also called antecollis), forward curvature of the lumbar region (also called camptocormia), or sideways curvature of the back (also called pleurothotonus or Pisa syndrome).
- Somnolence and sudden sleep episodes.
- Psychosis (e.g., similar to symptoms of schizophrenia).
- Visual impairment. You should undergo regular eye examinations during treatment with MIRAPEXIN.
- Severe heart or blood vessel disease. You should undergo regular blood pressure checks, especially at the beginning of treatment, to avoid postural hypotension (a drop in blood pressure when standing up).
- Increased restless legs syndrome. If you experience that the symptoms start earlier than usual at night (or even in the afternoon), are more intense, or affect larger areas of the affected limbs or affect other limbs. Your doctor may reduce the dose or discontinue treatment.
Inform your doctor if you, your family, or caregivers notice that you are developing impulses or urges to behave abnormally and cannot resist the impulse, instinct, or temptation to perform certain activities that may harm you or others. This is called impulse control disorder and may include behaviors such as gambling addiction, excessive eating or spending, abnormally high sexual appetite or interest. Your doctor may need to adjust the dose or discontinue treatment.
Inform your doctor if you, your family, or caregivers notice that you are developing mania (agitation, feeling elated or overexcited) or delirium (decreased consciousness, confusion, or loss of contact with reality). Your doctor may need to adjust the dose or discontinue treatment.
Inform your doctor if you notice symptoms such as depression, apathy, anxiety, fatigue, sweating, or pain when stopping or reducing treatment with MIRAPEXIN. If the problems persist for more than a few weeks, your doctor may need to adjust your treatment.
Inform your doctor if you notice inability to keep the trunk and neck straight and upright (axial dystonia). In this case, your doctor may decide to adjust or modify your treatment.
Children and adolescents
MIRAPEXIN is not recommended for use in children or adolescents under 18 years of age.
Other medications and MIRAPEXIN
Inform your doctor or pharmacist if you are taking, have recently taken, or may need to take any other medication. This includes medications, herbal remedies, natural foods, or nutritional supplements that you have obtained without a prescription.
You should avoid using MIRAPEXIN with antipsychotic medications.
Be cautious if you are using the following medications:
- cimetidine (for the treatment of excess acid and stomach ulcers)
- amantadine (which may be used in the treatment of Parkinson's disease)
- mexiletine (for the treatment of irregular heartbeats, a disorder known as ventricular arrhythmia)
- zidovudine (which may be used to treat acquired immunodeficiency syndrome [AIDS], a disease of the human immune system)
- cisplatin (for the treatment of various types of cancer)
- quinine (which may be used to prevent painful leg cramps that occur at night and to treat a type of malaria known as falciparum malaria [malignant malaria])
- procainamide (for the treatment of irregular heartbeat)
If you are taking levodopa, it is recommended to reduce the dose of levodopa when starting treatment with MIRAPEXIN.
Be cautious if you are using sedative medications (with a sedative effect) or if you drink alcohol. In these cases, MIRAPEXIN may affect your ability to drive and operate machinery.
Taking MIRAPEXIN with food, drinks, and alcohol
You should be cautious if you drink alcohol during treatment with MIRAPEXIN.
You can take MIRAPEXIN with or without food.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor before using this medication. Your doctor will indicate whether you should continue treatment with MIRAPEXIN.
The effect of MIRAPEXIN on the fetus is not known. Therefore, do not take MIRAPEXIN if you are pregnant unless your doctor indicates it.
MIRAPEXIN should not be used during breastfeeding. MIRAPEXIN may decrease milk production. Additionally, it may pass into breast milk and reach your baby. If the use of MIRAPEXIN is essential, breastfeeding should be discontinued.
Consult your doctor or pharmacist before taking any medication.
Driving and using machines
MIRAPEXIN may cause hallucinations (seeing, hearing, or feeling things that are not present). If this happens, do not drive or operate machines.
MIRAPEXIN has been associated with somnolence and sudden sleep episodes, especially in patients with Parkinson's disease. If you experience these side effects, do not drive or operate machinery. Inform your doctor if this happens to you.
3. How to take MIRAPEXIN
Follow the administration instructions of this medication exactly as indicated by your doctor. If in doubt, consult your doctor again. Your doctor will indicate the correct dosage.
You can take MIRAPEXIN with or without food. The tablets should be swallowed with water.
Parkinson's disease
The daily dose should be taken divided into 3 equal doses.
During the first week, the usual dose is 1 tablet of MIRAPEXIN 0.088 mg three times a day (equivalent to 0.264 mg per day):
1st week | |
Number of tablets | 1 tablet of MIRAPEXIN 0.088 mg three times a day |
Daily total dose (mg) | 0.264 |
This dose will be increased every 5-7 days according to your doctor's instructions until your symptoms are controlled (maintenance dose).
2nd week | 3rd week | |
Number of tablets | 1 tablet of MIRAPEXIN 0.18 mg three times a day or 2 tablets of MIRAPEXIN 0.088 mg three times a day | 1 tablet of MIRAPEXIN 0.35 mg three times a day or 2 tablets of MIRAPEXIN 0.18 mg three times a day |
Daily total dose (mg) | 0.54 | 1.1 |
The usual maintenance dose is 1.1 mg per day. However, it may be necessary to increase the dose further. If necessary, your doctor may increase the dose of tablets up to a maximum of 3.3 mg of pramipexole per day. It is also possible to reduce the maintenance dose to three tablets of MIRAPEXIN 0.088 mg per day.
Minimum maintenance dose | Maximum maintenance dose | |
Number of tablets | 1 tablet of MIRAPEXIN 0.088 mg three times a day | 1 tablet of MIRAPEXIN 0.7 mg and 1 tablet of MIRAPEXIN 0.35 mg three times a day |
Daily total dose (mg) | 0.264 | 3.15 |
Patient with kidney disease
If you have moderate or severe kidney disease, your doctor will prescribe a lower dose. In this case, you should take the tablets only once or twice a day. If you have moderate kidney failure, the usual starting dose is 1 tablet of MIRAPEXIN 0.088 mg twice a day. If you have severe kidney failure, the usual starting dose is 1 tablet of MIRAPEXIN 0.088 mg per day.
Restless legs syndrome
The dose is usually administered once a day, at night, 2-3 hours before bedtime.
During the first week, the usual dose is 1 tablet of MIRAPEXIN 0.088 mg once a day (equivalent to 0.088 mg per day):
1st week | |
Number of tablets | 1 tablet of MIRAPEXIN 0.088 mg |
Daily total dose (mg) | 0.088 |
This dose will be increased every 4-7 days according to your doctor's instructions until your symptoms are controlled (maintenance dose).
2nd week | 3rd week | 4th week | |
Number of tablets | 1 tablet of MIRAPEXIN 0.18 mg or 2 tablets of MIRAPEXIN 0.088 mg | 1 tablet of MIRAPEXIN 0.35 mg or 2 tablets of MIRAPEXIN 0.18 mg or 4 tablets of MIRAPEXIN 0.088 mg | 1 tablet of MIRAPEXIN 0.35 mg and 1 tablet of MIRAPEXIN 0.18 mg or 3 tablets of MIRAPEXIN 0.18 mg or 6 tablets of MIRAPEXIN 0.088 mg |
Daily total dose (mg) | 0.18 | 0.35 | 0.54 |
The daily dose should not exceed 6 tablets of MIRAPEXIN 0.088 mg or a dose of 0.54 mg (0.75 mg of pramipexole salt).
If you stop taking your tablets for a few days and want to resume treatment, you should start again with the smallest dose and then gradually increase the dose as you did the first time. Consult your doctor if you have any doubts.
Your doctor will evaluate your treatment after 3 months to decide whether to continue or not with the treatment.
Patient with kidney disease
If you have severe kidney disease, MIRAPEXIN may not be a suitable treatment for you.
If you take more MIRAPEXIN than you should
If you accidentally ingest too many tablets,
- consult your doctor or the emergency department of the nearest hospital immediately.
- you may experience vomiting, restlessness, or any of the side effects described in section 4, "Possible side effects".
If you forget to take MIRAPEXIN
Do not worry. Omit that dose completely and take the next dose at the correct time. Do not take a double dose to make up for the missed doses.
If you stop taking MIRAPEXIN
Do not stop your treatment with MIRAPEXIN without consulting your doctor first. If you need to stop your treatment with this medication, your doctor will gradually reduce your dose. This reduces the risk of worsening symptoms.
If you have Parkinson's disease, do not stop your treatment with MIRAPEXIN abruptly. Sudden interruption can cause a disorder called neuroleptic malignant syndrome, which can be a serious health risk. The symptoms include:
- akinesia (loss of muscle movement)
- muscle rigidity
- fever
- unstable blood pressure
- tachycardia (increased heart rate)
- confusion
- decreased level of consciousness (e.g., coma)
If you stop or reduce the dose of MIRAPEXIN, you may also experience a medical disorder called dopamine agonist withdrawal syndrome. The symptoms include depression, apathy, anxiety, fatigue, sweating, or pain. If you experience these symptoms, you should contact your doctor.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
4. Possible Adverse Effects
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them. The classification of adverse effects is based on the following frequencies:
Very Common | may affect more than 1 in 10 people |
Common | may affect up to 1 in 10 people |
Uncommon | may affect up to 1 in 100 people |
Rare | may affect up to 1 in 1,000 people |
Very Rare | may affect up to 1 in 10,000 people |
Frequency Not Known | cannot be estimated from the available data |
If you have Parkinson's disease, you may experience the following adverse effects:
Very Common:
- Dyskinesia (e.g., abnormal involuntary movements of the limbs)
- Somnolence
- Dizziness
- Nausea
Common:
- Need to behave in an unusual way
- Hallucinations (seeing, hearing, or feeling things that are not present)
- Confusion
- Fatigue
- Insomnia
- Excess fluid, usually in the legs (peripheral edema)
- Headache
- Hypotension (low blood pressure)
- Abnormal dreams
- Constipation
- Visual disturbance
- Vomiting
- Weight loss including loss of appetite
Uncommon:
- Paranoia (e.g., excessive concern for one's health)
- Delusion
- Excessive daytime somnolence and sudden episodes of sleep
- Amnesia (memory impairment)
- Hyperkinesia (increased movement and inability to remain still)
- Weight gain
- Allergic reactions (e.g., skin rash, itching, hypersensitivity)
- Fainting
- Heart failure (heart problems that can cause shortness of breath or swelling of the ankles)*
- Inadequate secretion of antidiuretic hormone*
- Restlessness
- Dyspnea (difficulty breathing)
- Hiccup
- Pneumonia (lung infection)
- Inability to resist the impulse, instinct, or temptation to perform an action that may be harmful to yourself or others, including:
- Strong impulse to gamble excessively despite serious personal or family consequences.
- Altered or increased sexual interest and behavior that is concerning to you or others, for example, increased sexual desire.
- Uncontrollable excessive shopping or spending.
- Binge eating (consuming large amounts of food in a short period) or compulsive eating (consuming more food than normal and more than needed to satisfy hunger).*
- Delirium (decreased consciousness, confusion, loss of contact with reality)
Rare:
- Mania (agitation, feeling elated or overexcited)
Frequency Not Known:
- After stopping or reducing treatment with MIRAPEXIN: depression, apathy, anxiety, fatigue, sweating, or pain (known as dopamine agonist withdrawal syndrome or DAWS) may occur.
Tell your doctor if you experience any of these behaviors; he will explain how to manage or reduce the symptoms.
For the adverse effects marked with *, it is not possible to provide a precise estimate of the frequency, as these adverse effects were not observed in clinical trials among 2,762 patients treated with pramipexole. The frequency category is probably no higher than "uncommon".
If you have restless legs syndrome, you may experience the following adverse effects:
Very Common:
- Nausea
- Symptoms that start earlier than usual, are more intense, or affect other limbs (worsening of restless legs syndrome).
Common:
- Changes in sleep patterns, such as insomnia and somnolence
- Fatigue
- Headache
- Abnormal dreams
- Constipation
- Dizziness
- Vomiting
Uncommon:
- Need to behave in an unusual way*
- Heart failure (heart problems that can cause shortness of breath or swelling of the ankles)*
- Inadequate secretion of antidiuretic hormone*
- Dyskinesia (e.g., abnormal involuntary movements of the limbs)
- Hyperkinesia (increased movement and inability to remain still)*
- Paranoia (e.g., excessive concern for one's health)*
- Delusion*
- Amnesia (memory impairment)*
- Hallucinations (seeing, hearing, or feeling things that are not present)
- Confusion
- Excessive daytime somnolence and sudden episodes of sleep
- Weight gain
- Hypotension (low blood pressure)
- Excess fluid, usually in the legs (peripheral edema)
- Allergic reactions (e.g., skin rash, itching, hypersensitivity)
- Fainting
- Restlessness
- Visual disturbance
- Weight loss including loss of appetite
- Dyspnea (difficulty breathing)
- Hiccup
- Pneumonia (lung infection)*
- Inability to resist the impulse, instinct, or temptation to perform an action that may be harmful to yourself or others, including:
- Strong impulse to gamble excessively despite serious personal or family consequences.*
- Altered or increased sexual interest and behavior that is concerning to you or others, for example, increased sexual desire.*
- Uncontrollable excessive shopping or spending.*
- Binge eating (consuming large amounts of food in a short period) or compulsive eating (consuming more food than normal and more than needed to satisfy hunger).*
- Mania (agitation, feeling elated or overexcited)*
- Delirium (decreased consciousness, confusion, loss of contact with reality)*
Frequency Not Known:
- After stopping or reducing treatment with MIRAPEXIN: depression, apathy, anxiety, fatigue, sweating, or pain (known as dopamine agonist withdrawal syndrome or DAWS) may occur.
Tell your doctor if you experience any of these behaviors; he will explain how to manage or reduce the symptoms.
For the adverse effects marked with *, it is not possible to provide a precise estimate of the frequency, as these adverse effects were not observed in clinical trials among 1,395 patients treated with pramipexole. The frequency category is probably no higher than "uncommon".
Reporting of Adverse Effects
If you experience any adverse effects, consult your doctor or pharmacist, even if they are possible adverse effects not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can help provide more information on the safety of this medicine.
5. Storage of MIRAPEXIN
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the carton after EXP. The expiration date is the last day of the month indicated.
Do not store above 30°C.
Store in the original packaging to protect from light.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any unused medicine. This will help protect the environment.
6. Contents of the Pack and Further Information
Composition of MIRAPEXIN
The active substance is pramipexole.
Each tablet contains 0.088 mg, 0.18 mg, 0.35 mg, or 0.7 mg of pramipexole as 0.125 mg, 0.25 mg, 0.5 mg, or 1 mg of pramipexole dihydrochloride monohydrate, respectively.
The other ingredients are mannitol, cornstarch, colloidal anhydrous silica, povidone K 25, and magnesium stearate.
Appearance and Packaging of the Product
The MIRAPEXIN 0.088 mg tablets are white, round, flat, and without a score.
The MIRAPEXIN 0.18 mg and MIRAPEXIN 0.35 mg tablets are white, oval, and flat. The tablets are scored on both sides and can be divided into two equal parts.
The MIRAPEXIN 0.7 mg tablets are white, round, and flat. The tablets are scored on both sides and can be divided into two equal parts.
All tablets have the company symbol Boehringer Ingelheim embossed on one side and the codes P6, P7, P8, or P9 on the other side, representing the tablet strength: 0.088 mg, 0.18 mg, 0.35 mg, and 0.7 mg, respectively.
All strengths of MIRAPEXIN are available in aluminum blister packs of 10 tablets per strip, in boxes of 3 or 10 blister packs (30 or 100 tablets). Not all pack sizes may be marketed.
Marketing Authorization Holder
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein
Germany
Manufacturer
Boehringer Ingelheim Pharma GmbH & Co. KG
Binger Strasse 173
55216 Ingelheim am Rhein
Germany
Rottendorf Pharma GmbH
Ostenfelder Strasse 51 – 61
59320 Ennigerloh
Germany
Boehringer Ingelheim France
100-104 avenue de France
75013 Paris
France
You can obtain further information on this medicine by contacting the local representative of the marketing authorization holder:
België/Belgique/Belgien SCS Boehringer Ingelheim Comm.V Tel: +32 2 773 33 11 | Lietuva Boehringer Ingelheim RCV GmbH & Co KG Lietuvos filialas Tel: +370 5 2595942 |
| Luxembourg/Luxemburg SCS Boehringer Ingelheim Comm.V Tel: +32 2 773 33 11 |
Ceská republika Boehringer Ingelheim spol. s r.o. Tel: +420 234 655 111 | Magyarország Boehringer Ingelheim RCV GmbH & Co KG Magyarországi Fióktelepe Tel: +36 1 299 89 00 |
Danmark Boehringer Ingelheim Danmark A/S Tlf: +45 39 15 88 88 | Malta Boehringer Ingelheim Ireland Ltd. Tel: +353 1 295 9620 |
Deutschland BIOTHERAX biochemisch-pharmazeutische Gesellschaft mbH Tel: +49 (0) 800 77 90 900 | Nederland Boehringer Ingelheim b.v. Tel: +31 (0) 800 22 55 889 |
Eesti Boehringer Ingelheim RCV GmbH & Co KG Eesti filiaal Tel: +372 612 8000 | Norge Boehringer Ingelheim Danmark Norwegian branch Tlf: +47 66 76 13 00 |
Ελλάδα Boehringer Ingelheim Ελλάς Movoπpóσωπη A.E. Tηλ: +30 2 10 89 06 300 | Österreich Boehringer Ingelheim RCV GmbH & Co KG Tel: +43 1 80 105-7870 |
España Boehringer Ingelheim España, S.A. Tel: +34 93 404 51 00 | Polska Boehringer Ingelheim Sp.zo.o. Tel: +48 22 699 0 699 |
France Boehringer Ingelheim France S.A.S. Tel: +33 3 26 50 45 33 | Portugal Boehringer Ingelheim Portugal, Lda. Tel: +351 21 313 53 00 |
Hrvatska Boehringer Ingelheim Zagreb d.o.o. Tel: +385 1 2444 600 | România Boehringer Ingelheim RCV GmbH & Co KG Viena – Sucursala Bucuresti Tel: +40 21 302 28 00 |
Ireland Boehringer Ingelheim Ireland Ltd. Tel: +353 1 295 9620 | Slovenija Boehringer Ingelheim RCV GmbH & Co KG Podružnica Ljubljana Tel: +386 1 586 40 00 |
Ísland Vistor hf. Sími: +354 535 7000 | Slovenská republika Boehringer Ingelheim RCV GmbH & Co KG organizacná zložka Tel: +421 2 5810 1211 |
Italia Boehringer Ingelheim Italia S.p.A. Tel: +39 02 5355 1 | Suomi/Finland Boehringer Ingelheim Finland Ky Puh/Tel: +358 10 3102 800 |
Κύπρος Boehringer Ingelheim Ελλάς Movoπpóσωπη A.E. Tηλ: +30 2 10 89 06 300 | Sverige Boehringer Ingelheim AB Tel: +46 8 721 21 00 |
Latvija Boehringer Ingelheim RCV GmbH & Co KG Latvijas filiale Tel: +371 67 240 011 | United Kingdom (Northern Ireland) Boehringer Ingelheim Ireland Ltd. Tel: +353 1 295 9620 |
Date of Last Revision of this Leaflet:{MM/AAAA}.
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.
- Country of registration
- Average pharmacy price7.62 EUR
- Active substance
- Prescription requiredYes
- Manufacturer
- This information is for reference only and does not constitute medical advice. Always consult a doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to MIRAPEXIN 0.18 mg TABLETSDosage form: TABLET, 0.088 mgActive substance: pramipexoleManufacturer: Boehringer Ingelheim International GmbhPrescription requiredDosage form: TABLETActive substance: pramipexoleManufacturer: Boehringer Ingelheim International GmbhPrescription requiredDosage form: MODIFIED-RELEASE TABLET, 0.26 of pramipexoleActive substance: pramipexoleManufacturer: Boehringer Ingelheim International GmbhPrescription required
Online doctors for MIRAPEXIN 0.18 mg TABLETS
Discuss questions about MIRAPEXIN 0.18 mg TABLETS, including use, safety considerations and prescription review, subject to medical assessment and local regulations.
Frequently Asked Questions
